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Abstract
The term nephronophthisis-related ciliopathies (NPHP-RC) describes a group of rare autosomal-
recessive cystic kidney diseases, characterized by broad genetic and clinical heterogeneity. NPHP-
RC is frequently associated with extrarenal manifestations and accounts for the majority of 
genetically caused chronic kidney disease (CKD) during childhood and adolescence. Generation 
of a molecular diagnosis has been impaired by this broad genetic heterogeneity. However, recently 
developed high-throughput exon sequencing techniques represent powerful and efficient tools to 
screen large cohorts for dozens of causative genes. Therefore, we performed massively 
multiplexed targeted sequencing using the modified molecular inversion probe (MIPs) strategy in 
an international cohort of 384 patients diagnosed with NPHP-RC. As a result, we established the 
molecular diagnoses in 81/384 unrelated individuals (21.1%). We detected 127 likely disease-
causing mutations in 18 of 34 evaluated NPHP-RC genes, 22 of which were novel. We further 
compared a subgroup of current findings to the results of a previous study in which we used an 
array-based microfluidic PCR technology in the same cohort. While 78 likely disease-causing 
mutations were previously detected by the array-based microfluidic PCR, the MIPs approach 
identified 94 likely pathogenic mutations. Compared to the previous approach, MIPs re-detected 
66 out of 78 variants and 28 previously unidentified variants, for a total of 94 variants. In 
summary, we demonstrate that the modified MIPs technology is a useful approach to screen large 
cohorts for a multitude of established NPHP genes in order to identify the underlying molecular 
cause. Combined application of two independent library preparation and sequencing techniques, 
however, may still be indicated for Mendelian diseases with extensive genetic heterogeneity in 
order to further increase diagnostic sensitivity.
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INTRODUCTION
The term nephronophthisis-related ciliopathies (NPHP-RC) summarizes a group of rare 
autosomal-recessive cystic kidney diseases including nephronophthisis (NPHP), Senior-
Løken syndrome (SLS), Joubert syndrome (JBTS), and Meckel-Gruber-syndrome 
(MKS).1, 2 NPHP-RC are genetically heterogeneous disorders, characterized by mutations in 
genes which encode proteins that localize to primary cilia, basal bodies, or centrosomes. The 
disruption of the ciliary function results in a broad phenotypic spectrum which is 
collectively termed “ciliopathies”.3 NPHP-RC account for the majority of genetic end-stage 
renal disease (ESRD) during the first three decades of life. The most prominent renal 
features are increased echogenicity and corticomedullary cysts on ultrasound. Renal 
histology reveals tubular atrophy, basement membrane disintegration, interstitial fibrosis, 
and cyst formation. About 15% of the affected individuals with NPHP-RC show extrarenal 
organ involvement, most notably, progressive retinal dystrophy defined as SLS. Cerebellar 
malformations such as mid-hindbrain malformation and cerebellar vermis hypoplasia/aplasia 
are commonly observed in individuals with JBTS and are characterized by the “molar tooth 
sign” (MTS) in brain imaging studies.4 These malformations are associated with numerous 
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neurological features including developmental delay, intellectual disability, muscle 
hypotonia, ataxia, oculomotor apraxia, nystagmus, and abnormal respiratory control.4 MKS 
represents the most severe manifestation of the NPHP-RC spectrum as a perinatally lethal 
ciliopathy.5 To date, more than 90 genes have been implicated in the pathogenesis of 
ciliopathies, accounting for approximately 50% of affected individuals.6 JBTS and MKS are 
caused by mutations in a subset of these genes including: MKS1 (MIM# 609883), B9D1 
(MIM# 614144), B9D2 (MIM# 611951), AHI1 (MIM# 608894), INPP5E (MIM# 613037), 
ARL13B (MIM# 608922), TMEM216 (MIM# 613277), CC2D2A (MIM# 612013), KIF7 
(MIM# 611254), TCTN1 (MIM# 609863), TCTN2 (MIM# 613846), TCTN3 
(MIM#614815), CEP41 (MIM# 610523), IFT172 (MIM#615630), CSPP1 (MIM#615636), 
RPGRIP1L (MIM#611560), OFD1 (MIM#300804), TMEM138 (MIM#614465), TMEM231 
(MIM#614970), PDE6D (MIM#615665), and TMEM237 (MIM# 614423).7–26 Due to the 
large number of established NPHP–RC genes, molecular genetic diagnostics remains a 
major challenge and requires further technical advances.
Recently, high-throughput and next-generation sequencing (NGS) platforms have become 
widely available and allow massively parallel low-cost sequencing.27, 28 Previous studies 
from our group have established a microfluidic multiplex PCR technology with consecutive 
NGS. Screening for multiple established NPHP genes yielded the molecular cause in about 
13% of cases in large cohorts of patients with NPHP-RC.29, 30 The recently developed 
Modified Molecular Inversion probe strategy (MIPs) represents another technique that 
allows rapid and cost-effective sequencing of candidate genes in large cohorts.31 In the 
present study, we applied the MIPs technology to 384 samples from affected unrelated 
individuals with NPHP-RC. We captured and amplified 760 coding exons of 34 established 
NPHP-RC genes, including NPHP1-NPHP12, PKHD1, the gene causing autosomal-
recessive cystic kidney disease (ARPKD), and 21 established JBTS/MKS genes. We 
established the molecular diagnoses in 81/384 unrelated individuals (21.1%). Altogether, we 
detected 127 mutations. In addition, we compared the sensitivity, specificity, and costs of the 
two above mentioned targeted high-throughput technologies in our cohort.
MATERIALS AND METHODS
Human subjects
We obtained blood samples, pedigrees, and clinical information after receiving informed 
consent (www.renalgenes.org). Approval for experiments on humans was obtained from the 
University of Michigan and the Boston Children’s Hospital Institutional Review Boards. A 
total cohort of 384 affected individuals diagnosed with NPHP-RC based on published 
clinical criteria were sequenced using the MIPs technology.32 This cohort contains 84 
unrelated individuals from families with multiple affected individuals, and 300 single 
affected individuals. Consanguinity was known to be present in 67 (17.3%) families. Prior to 
study enrollment, individuals with homozygous deletions of NPHP1 were excluded by using 
a multiplex PCR-based deletion analysis as previously described.33
Schueler et al. Page 3
J Med Genet. Author manuscript; available in PMC 2016 October 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Primer design and evaluation for the MIP system
MIPs were designed to target 760 coding exons of 34 established NPHP-RC genes 
(Supplementary Table 1) using hg19 human genome reference and the dbSNP132 database 
to identity polymorphisms that might interfere with hybridization. Each MIP targeted a 
specific 112 bp genomic region using flanking extension (16 to 20 bp) and ligation (20 to 24 
bp) arms. Following synthesis (IDT, Coralville, IA), MIPs were standardized to 100uM, and 
equimolar amounts of each MIP were pooled.31
Target DNA enrichment by the MIP System
Target-specific MIPs hybridized to 100ng of genomic DNA input followed by polymerase-
mediated gap filling and ligation. The captured DNA was PCR amplified using universal 
primers containing Illumina flowcell adaptor sequences and a unique 8-base barcode. 
(Illumina, San Diego, CA). Next, four sets of 96 barcoded sample libraries were pooled, and 
each was purified using 1.8X AMPure XP beads (Beckman Coulter, Brea, CA). The 
appropriate product size was confirmed by agarose gel electrophoresis.31
MIP target rebalancing and next-generation sequencing
A pilot MIP capture was performed on a subset of samples and sequenced using the Illumina 
MiSeq. MIP targets were rebalanced by spiking the poorest performing (bottom 15% by read 
depth) MIPs at 10x. The rebalanced MIP pool was used to create the 384 individual sample 
libraries as described above. Pooled libraries were sequenced on three lanes of an Illumina 
HiSeq 2000 instrument using 101 bp paired-end reads.31
Bioinformatics pipeline
Raw sequence reads were processed and aligned to the hg19 human reference sequence 
(UCSC Genome Browser) using the Burrows-Wheeler Aligner (BWA, version 0.5.9). BAM 
files were generated with Picard tools (see Web Resources), followed by single-nucleotide 
variant (SNV) and indel calling using the Genome Analysis Toolkit’s Unified-Genotyper 
(GATK version 2.2) with the depth of coverage parameter set to 5,000. Called variants 
failing to meet the following quality metrics were removed from further analysis: quality > 
30, read depth > 8, quality by depth > 5. A window of 10 was set for clustered variants. 
Variants were annotated with SeattleSeq (see Web Resources) and further filtered against 
controls from the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing 
Project Exome Variant Server (EVS) ESP6500 dataset with the use of an observed minor 
allele frequency threshold < 1%.31 Variants were ranked by the criteria of whether mutations 
were likely to truncate the conceptual reading frame (nonsense, frameshift, and obligatory 
splice mutations), whereas missense variants were ranked by the evolutionary conservation 
and by predicting the impact on the encoded protein using web-based programs (PolyPhen2, 
Phylo-P score, CADD score, Mutation Taster, SIFT).
NPHP1 copy number variation detection by the MIP system
The read depth of each MIP was normalized to the overall read depth for each sample, and 
then a standardized Z-score was calculated. Underperforming MIPs with a median coverage 
<20X were removed. Singular value decomposition (SVD) was used to reduce systematic 
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noise. Using the SVD-adjusted Z-scores, we identified samples where the majority of 
NPHP1-targeted MIPs had Z-scores >= 2.0 or <= −2.0.31 Individual A2527, who was 
examined in an independent array previously, served as a positive control for successful 
CNV calling.
Sanger sequencing confirmation and segregation analysis
Variants/mutations detected by NGS and predicted to be detrimental were subsequently 
confirmed by Sanger sequencing using original DNA samples from the respective affected 
individuals as PCR template. Whenever DNA was available from the index person, the 
affected siblings, and parents, we performed segregation analysis. Polymerase chain reaction 
(PCR) was performed using a touchdown protocol described previously.34 Sequencing was 
performed using Mastercycler pro (Eppendorf, Hamburg, Germany). Sequence traces were 
analyzed using CLC Genomics Workbench™ software (CLC-bio, Aarhus, Denmark).
RESULTS
NGS and mapping statistics
Sequencing was performed on an Illumina HiSeq 2000 platform after capture and 
amplification of 34 NPHP-RC genes in 384 affected individuals (384 families) with NPHP-
RC using the Modified Molecular Inversion Probe technique (Figure 1, Supplementary Table 
2). The total output was 361 million reads of 101 bases yielding an average of 940 thousand 
reads per DNA sample. Alignment using the Burrows-Wheeler Aligner (BWA, version 
0.5.9) software to the hg19 human reference sequence (UCSC Genome Browser) resulted in 
mean exon coverage of 505, with greater than 97% of targeted exons having ≥25-fold 
average coverage (Supplementary Figure 1). Due to low DNA quality, sequencing failed for 
2 samples, while 7 samples have 10 and 1 sample 13% coverage at 25x.
Variant filtering, validation and parameter setting
Altogether, we obtained 27,133 single nucleotide variants and 646 insertion/deletion (indel) 
variants derived from the 384 individuals. In total, 20,371 (exonic and intronic) variants 
showed a minor allele frequency (MAF) of >1% across the dataset, which were considered 
to be frequent SNPs according to the EVS database and, therefore excluded.
As previously reported,31 we removed variants from further analysis whenever the following 
parameters were present: coverage < 8x, quality score < 30, and a quality by depth < 5. 
Variants below this threshold were considered as likely “false positives”. Furthermore, we 
included only missense variants that showed an evolutionary conservation down to Ciona 
intestinalis, a PolyPhen2-score >0.9 and a MAF <1% across the dataset. Alternatively, 
variants were included when they had previously been reported as disease-causing according 
to the HGMD®-Professional mutation database “Biobase” and were conserved down to 
Danio rerio.
After filtering and ranking, 189 variants, including 110 potentially protein-truncating 
mutations (such as nonsense, frameshift, and obligatory splice site mutations), and 79 
missense variants/mutations, were selected for standard Sanger sequencing. We were able to 
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confirm 93 of the 110 potential truncating mutations (85%) and 70 of the 79 selected 
missense variants (89%). A total of 163 out of 189 variants (specificity: 86%) were 
confirmed by Sanger sequencing. However, 35 of the 163 confirmed potential mutations 
were excluded as common SNPs according to the 1000 genomes, dbSNP138, EVS and 
ExAC Browser database or have been reported as homozygous SNPs. The remaining 
mutations were compared to the HGMD®-Professional mutation database “Biobase” 
(HGMD 2015.2 (copyright Cardiff University 2015)) and defined as novel if not present.
Sensitivity for detecting known variants and comparison of two approaches
In order to calculate the sensitivity of the MIPs technology in this study, we compared the 
detected disease-causing mutations within the coding regions of 12 established NPHP genes 
(NPHP1-NPHP12) to our previous mutation analysis.29, 30 By using an array-based 
microfluidic PCR technology with NGS, we previously identified and Sanger confirmed 78 
variants, which explained the underlying molecular cause in 49/384 families of the same 
cohort. 29, 30 Overall, 66 out of these 78 mutations were re-detected in the present study 
(“mutation” sensitivity: 85%). In particular, eight mutations were not re-detected due to low 
coverage, giving a sensitivity of 94% (66/70) at covered basepairs. A four basepair 
duplication in IQCB1 was missed in three individuals because one of the flanker arms of this 
MIP overlapped with the duplication. For three individuals the reason why the MIPs 
technology missed the previous detected mutation remains unclear (Figure 2, Supplementary 
Table 3).
The estimated costs for library preparation and sequencing of 384 individuals using the 
modified MIPs technology are US$21,00031 whereas the calculated costs for sequencing the 
same cohort using an array-based microfluidic PCR technology amount is US$18,50029 in 
total. These costs comprise reagents and primers but do not include costs for acquisition of 
additional machinery, which is the case in the microfluidic PCR approach (Supplementary 
Table 4, Supplementary Figure 2). Concerning the hands-on time for library preparation, 
sequencing, and bioinformatics pipeline analysis, there are no major differences between 
both methods: approx. 142 hours for the MIPs technology and 148 hours if using an array-
based microfluidic PCR technology.
Identification of genetic causes in a cohort of 384 individuals
The combination of capturing all coding exons of 34 established NPHP-RC genes by using 
the MIPs technology in an international cohort of 384 unrelated affected individuals (384 
families) diagnosed with NPHP-RC revealed the molecular diagnosis in 81 individuals (81 
families). Furthermore, 26 single heterozygous mutations were detected in 26 individuals, 15 
of which were missense variants, and 11 of which were single heterozygous nonsense 
variants. Additional Sanger sequencing of all remaining coding exons of the genes, wherein 
a single heterozygous variant was detected, revealed two additional heterozygous missense 
mutations, which segregated within the affected status. Copy number variation (CNV) 
analysis for NPHP1 revealed nine heterozygous deletions and six heterozygous duplications 
including the positive control (individual A2527); none was previously detected by using a 
multiplex PCR-based deletion analysis.
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In summary, by massively parallel targeted sequencing using MIPs strategy we identified the 
molecular diagnosis in 81 of 384 (21.1%) unrelated patients/families. Recessive mutations 
were identified in the following genes (number of unrelated patients/families in 
parentheses): CEP290 (15), PKHD1 (10), IQCB1 (10), NPHP3 (9), NPHP1 (8), TMEM67 
(7), NPHP4 (6), INVS (3), CC2D2A (2), CEP164 (2), TTC21B (2), SDCCAG8 (1), IFT172 
(1), OFD1 (1), TMEM216 (1), TMEM237 (1), TCTN1 (1), and AHI (1) (Supplementary 
Table 2). No causative mutations were identified in the genes GLIS2 (NPHP7), RPGRIP1L 
(NPHP8), NEK8 (NPHP9), ARL13B, B9D1, B9D2, C5ORF42, CEP41, INPP5E, KIF7, 
MKS1, TCTN2, TCTN3, TMEM231, TMEM138, and CSPP1. Overall, we identified 30 
independent families with homozygous mutations, five families with hemizygous mutations, 
and 46 families with compound heterozygous mutations. In 51 individuals truncating 
mutations (nonsense, frameshift or obligatory splice-site mutations) were found on both 
alleles, whereas 14 affected individuals showed one truncating mutation in combination with 
a non-synonymous missense mutation. The remaining 16 individuals exhibited missense 
mutations on both alleles. After additional evaluation and Sanger sequencing of all coding 
regions and intron/exon boundaries in the respective genes, 11 families remained with only 
one heterozygous truncating mutation. We discovered a total of 22 novel pathogenic 
mutations in the following genes (number of families in parentheses): PKHD1 (6), NPHP1 
(4), CC2D2A (2), CEP290 (2), NPHP4 (2), NPHP3 (2), INVS (1), TTC21B (1), OFD1 (1), 
and TMEM237 (1) (Table 1).
DISCUSSION
Massively multiplex targeted sequencing of 34 established NPHP-RC genes using the MIPs 
strategy in an international cohort of 384 affected individuals with NPHP-RC identified the 
molecular cause in 81 families. Altogether our study identified 127 pathogenic mutations. 
CEP290 was found most commonly mutated (15 families). Interestingly, mutations in 
PKHD1 and IQCB1 were the second most frequent molecular cause in our cohort (10 
affected families each). This shows that the clinical presentation of ARPKD may mimic the 
NPHP-RC phenotype and is not necessarily distinguishable without the use of molecular 
genetics in clinical practice.
Combined with our previous mutation analysis using an array-based microfluidic multiplex 
PCR technology, we obtain a representative distribution of genes in a cohort of individuals 
with NPHP-RC pre-screened for the most common mutation, the NPHP1 deletion.30 After 
exclusion of the presence of a homozygous NPHP1 deletion, a disease-causing mutation was 
identified in 21% of the cases, leaving almost 80% of cases genetically unsolved when 
analyzing 34 established NPHP, ARPKD, and JBST genes (Supplementary Table 2) (Figure 
1).
Twenty-six individuals carry single heterozygous variants, which do not explain the 
phenotype based on an autosomal recessive hypothesis; however, it is possible that second 
variants were not detected in the few areas of low coverage or in non-coding regions. These 
unsolved cases may be explained by missed mutations in the targeted genes, mutations in 
other established NPHP-RC genes that were not part of this study, or by mutations in genes 
which phenocopy NPHP-RC, such as e.g. CLCNKB, COL4A5, and AGXT.35 Secondly, 
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these cases may be explained due to mutations in genes, which have not yet been implicated 
as a molecular cause of NPHP-RC. This fact further implies the presence of genetic 
heterogeneity in individuals with NPHP-RC. Lastly, a significant fraction may be explained 
by unidentified mutations (false negatives), as indicated by a mutation sensitivity of 85% 
when compared to our previous analysis of the same cohort (Figure 2, Supplementary Table 
3). As a conclusion, combination of two library preparation methods may be indicated in 
order to warrant sufficient sensitivity, at least in a diagnostic setting.
In summary, we demonstrate that the modified molecular inversion probe (MIPs) strategy is 
a useful library preparation method for targeted sequencing approaches and mutation 
analysis in large cohorts of individuals with NPHP-RC. Whereas Sanger sequencing has 
been the gold standard over the past 30 years, it has been proven to be tedious and 
expensive, especially for large cohorts and genetically heterogeneous conditions like NPHP-
RC. Recent developments in high-throughput library preparation and massively parallel 
sequencing offer various novel and efficient methods that decrease sequencing time and 
costs. Due to the increasing number of established genes, the relevance and utility of high-
throughput sequencing techniques is indispensable for molecular genetic diagnostics.
As about 50% of affected individuals with NPHP-RC remain genetically unsolved, non-
targeted sequencing approaches like whole exome/genome sequencing (WES/WGS) are 
needed to identify new candidate disease genes. For mutation analysis of panels of known 
disease genes in large cohorts, however, WES is still not cost-efficient. In our case, the price 
tag for sequencing a cohort of 384 affected individuals using WES would amount to about 
US$268,800 assuming US$700 per individual, whereas the costs for MIPs or array-based 
microfluidic PCR technology added up to about US$20,000 (approx. US$50–100 per 
individual for > 200 samples) (Supplementary Table 4, Supplementary Figure 2). For the 
proposed targeted sequencing approaches, though, a minimal cohort size of at least 100 
probands is recommended in order to run them cost-efficiently (Supplementary Figure 2). 
While WES/WGS are essential tools to identify novel candidate disease genes in single 
cases, targeted high-throughput screening technologies, such as MIPs, can also be helpful to 
analyze large cohorts with the same phenotype to corroborate these candidates through 
detection of additional unrelated individuals with mutations in the same gene.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distribution of molecular NPHP-diagnoses in 18 established NPHP-RC genes, detected 
in an international cohort of 384 individuals with NPHP-RC
A) Number of families detected with molecular diagnoses in 18 established NPHP-RC 
genes, which are sorted from left to right by frequency. All individuals were previously 
screened for the presence of a homozygous NPHP1 deletion prior to being entered into the 
present study. B) Percentage of individuals with a molecular diagnosis versus individuals 
without a molecular diagnosis in our cohort of 384 unrelated individuals diagnosed with 
NPHP-RC (left); distribution of molecular diagnoses across 18 NPHP-RC genes (right).
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Figure 2. Comparison of two targeted high-throughput library preparation approaches; MIPs 
and array-based microfluidic multiplex PCR
A) Schematic design of general work flow of the two high-throughput mutation analysis 
approaches: Modified Molecular Inversion probe (MIPs) technique (on the left) and array-
based microfluidic multiplex PCR technology (Fluidigm™) (on the right). For both 
techniques library preparation was followed by consecutive next-generation sequencing 
(NGS). B) Overlapping findings in NPHP1-NPHP12 by application of either mutation 
analysis approach: MIPs technique (blue circle) and Fluidigm™ technology (yellow circle). 
66 (61%) variants were detected by both methods (overlapping circles). By applying MIPs 
28 (26%) additional variants were detected. By using the array-based microfluidic multiplex 
PCR (Fluidigm™) approach, an additional 12 (11%) variants were identified (see also 
Supplementary Table 2, Supplementary Table 3).
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Table 1
Number of novel mutations detected in this study compared to previously reported mutations (HGMD®-
Professional “Biobase”, 2015) in the genes NPHP1, INVS, NPHP3, NPHP4, CEP290, TTC21B, PKHD1, 
CC2D2A, OFD1, and TMEM237.
Gene Novel (# mut) Biobase (# mut) Percent added
NPHP1 4 42 10%
INVS / NPHP2 1 26 4%
NPHP3 2 53 4%
NPHP4 2 90 2%
CEP290 / NPHP6 2 186 1%
TTC21B / NPHP12 1 39 3%
PKHD1 6 388 2%
CC2D2A 2 52 4%
OFD1 1 129 1%
TMEM237 1 6 17%
total 22 1,011
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